It's a tough time for chip makers, particularly those in the [personal computer] market, TheStreet's Jim Cramer, co-portfolio manager of the Action Alerts PLUS portfolio, said on CNBC's "Stop Trading" segment.
He also likes Horizon Pharma (HZNP) - Get Report, pointing out analysts at UBS raised their price target on the stock to $40 from $32. While shares have doubled this year, "it can go up another 10%," Cramer said.
As for Greece, he sees it as unlikely that a debt deal will get done this weekend.
At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.